Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.76 |
| ▸ | MAOB | P27338 | 6/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SDHA | P31040 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CALML3 | P27482 | 1/20 | 0.76 |
| ▸ | F10 | P00742 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188758 | 1.00 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27361465 | 0.95 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7818278 | 0.95 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7818282 | 0.95 | MAOA (0.71) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6988639 | 0.93 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6988646 | 0.93 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987968 | 0.92 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6987961 | 0.92 | MAOB (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6991813 | 0.91 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6991822 | 0.91 | MAOA (0.75) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0750618-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2003-02-19 | — | — | EP | claimed |
| EP-1546140-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wockhardt Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235900-A1 | Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages | WOCKHARDT LIMITED (IN) | 2004-11-25 | — | — | US | disclosed |
| WO-2004007488-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
| EP-1030852-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | UPJOHN CO (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-0750618-B1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UPJOHN CO (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1030852-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-30 | — | — | EP | disclosed |
| US-5998406-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999024428-A1 | OXAZOLIDINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| US-5668286-A | ANTIBIOTIC | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235900-A1 | Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages | OXA1L, VIP, CYP51A1 | MAOA 2006/4885MAOB 1589/4885PTGS1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.